The FDA approves a new weight loss medication which reduces the weight of patients by 18%
The Eli Lilly product is already on the market under the name of Mounjaro and used to treat diabetes.
Even if the subject of weight loss has long been part of the conversation of well-being overall, recent developments have changed the way we approach. Prescription drugs including ozempic - which was approved for the treatment of diabetes and prescribed out of AMM for weight loss - and the approved obesity medication that Wegovy changed the process of loss of books recently for those who prescribed them. And now, the list of potential options for patients is longer after the US Food & Drug Administration (FDA) has approved Zepbound as a weight loss medication. Read the rest to learn more about the prescription medication that has proven to reduce the weight of certain patients by 18%.
In relation: Countries place new prohibitions on Ozempic-Can the United States follow?
Zepbound has been approved as an obesity treatment drug by the FDA.
On November 8, the FDA announced that it had approved Zepbound for Chronic weight management and the treatment of diabetes. The drug, named shooting, is Produced by Eli Lilly and will rival the most directly with the popular Wegovy obesity medication of Novo Nordisk, The New York Times reports.
Although the name Zepbound can be new, the shooting is already available on the market under the Mounjaro brand, which was previously approved for the treatment of type 2 diabetes in adults. Zepbound can be prescribed to overweight patients who have at least one condition related to obesity, including high blood pressure, type 2 diabetes or high cholesterol, depending on the release of the FDA.
Zepbound works in a similar way to Wegovy by imitating the GLP-1 hormone, which helps reduce hunger and slow down a person's food intake. It is also administered by injection once a week with a maximum dose of 15 mg per week, according to the FDA.
"Obesity and overweight are serious conditions that can be associated with some of the main causes of death such as heart disease, brain vascular accidents and diabetes", " John Sharretts , MD, director of the diabetes division, lipid disorders and obesity, for the FDA, said in the agency's press release. "Given the increase in obesity and overweight rates in the United States, today's approval responds to an unmet medical need."
In relation: 4 foods that increase the same weight loss hormone as Ozempic, experts say .
Clinical trials have shown that the drug can help patients with significant weight loss.
The first signs of Zepbound's efficiency come from a small 2017 study with 300 people with type 2. The results revealed that patients who took the medication for three months have lost at least 13% of their body weight, The New York Times reports.
The following study conducted a randomized double -blind and placebo -controlled clinical trial using using 2,519 adult patients with obesity or overweight. Participants received doses of 5 mg, 10 mg or 15 mg once a week for 72 weeks.
The results show that patients at all dose levels who received the drug have seen at least one body weight reduction of five percent compared to those who received a placebo, according to the release of the FDA. And those of the group who received the highest dose lost an average of 18% of their body weight compared to the placebo group. In comparison, patients taking a comparable dose of Wegovy experienced an average reduction in body weight by 15%, according to The temperature .
In relation: FDA problems .
The drug could help provide problems and potentially reduce cost.
The FDA approval also occurs while the flood popularity of drugs like Ozempic and Wegovy has created shortages for patients. In fact, Novo Nordisk Wegovy limited lower dosages Required for new patients in order to prioritize their supplies for those who already take the drug, reports CNN. AE0FCC31AE342FD3A1346EBB1F342FCB
Zepbound's availability could also help to come down The cost of medication as competition increases. The drug will cost around $ 1,060 per month before insurance when it is sold later this month, according to a press release from Eli Lilly. In comparison, the company currently sets the price of the Mounjaro list at $ 1,023 per month, while Ozempic and Wegovy de Novo Nordisk are respectively $ 936 and $ 1,349 per month.
The company highlighted the price difference of 20% between IT and its competitor when it was announced, saying that it had spoken to employers for payment decisions concerning employee insurance. "They said that the price of the list was something that was a factor in their decision to extend access to people who need these drugs," Mike Mason , president of Lilly Diabetes and Obesity Division, told journalists on November 8, according to CNN.
In relation: A 56 -year -old woman dies from the alleged ozempic side effects, family complaint .
The drug still has familiar side effects.
Similar to its competitors, Zepbound has always proven to cause side effects that mainly affect the gastrointestinal system. These include "nausea, diarrhea, vomiting, constipation, abdominal discomfort (stomach) and pain", and other symptoms such as "injection site reactions, fatigue, hypersensitivity (allergic) (allergic) (allergic) (allergic) (allergic) (allergic) Generally fever and disease eruption of gastroesophageal reflux, according to the release of the FDA.
But even if the debate on the use of drugs by certain patients continues, some experts consider the release of the drug as an important step to help fight a public health problem.
"Barely a few years ago, it would be difficult to imagine two drugs such as semaglutide and shooting which cause weight loss that has only been observed before when people have undergone bariatric surgery", " Susan Yanovski , Codirector of the Obesity Research Office at the National Institute of Diabetes and Digestive and Renal Diseases, told The temperature .
Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.
In relation: For more information, register for our daily newsletter .
